Rxsight, Inc. (RXST) Stock Price & Analysis
Rxsight, Inc. (RXST) fell 0.81% to USD 4.91 as of June 10, 2026 at 03:35 UTC, according to Nexqual real-time market data.
RXST last closed at USD 4.95; the session ranged USD 4.82–5.15 on volume of 1,063,826 shares. Market capitalization is $203.26M, with a 52-week range of USD 4.7–15.81 (NGM). Source: Nexqual, June 10, 2026 at 03:35 UTC.
Key Statistics (as of June 10, 2026 at 03:35 UTC)
| Price | USD 4.91 |
|---|---|
| Change | ▼ 0.81% (down) |
| Previous Close | USD 4.95 |
| Open | USD 5 |
| Day Range | USD 4.82 – 5.15 |
| 52-Week Range | USD 4.7 – 15.81 |
| Volume | 1,063,826 shares |
| Market Cap | $203.26M |
| Exchange | NGM |
Technical Analysis (RXST)
Nexqual's technical model rates RXST "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:35 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.86 (oversold) |
| vs SMA50 | Below (USD 6.35) |
| MACD | -0.44 (negative) |
Analyst Ratings (RXST)
Wall Street analysts rate RXST "Hold" based on 7 analysts, with a mean price target of USD 8.79 (range USD 7.5–11), per Nexqual as of June 10, 2026 at 03:35 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 8.79 |
| High Target | USD 11 |
| Low Target | USD 7.5 |
| Buy / Hold / Sell | 1 / 6 / 2 |
Earnings (RXST)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.2 |
| Revenue Estimate | $32.07M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.19 vs est -0.15 ▼ miss |
| 2025-12-31 | USD -0.03 vs est -0.2 ▲ beat |
| 2025-09-30 | USD -0.04 vs est -0.26 ▲ beat |
| 2025-06-30 | USD -0.08 vs est -0.11 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:35 UTC.
Financials & Fundamentals (RXST)
| Total Revenue | $127.48M |
|---|---|
| Revenue Growth (YoY) | -18.50% |
| Gross Margin | +77.02% |
| Operating Margin | -57.71% |
| Profit Margin | -36.59% |
| ROE | -17.06% |
| Debt / Equity | 4.05 |
| Current Ratio | 10.2 |
| Total Cash | $217.88M |
| Total Debt | $10.83M |
| Free Cash Flow | $-969,250 |
Source: Nexqual, June 10, 2026 at 03:35 UTC.
Financial Health Score (RXST)
Nexqual rates Rxsight, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:35 UTC.
| Growth | Weak — Revenue -4% YoY (annual), declining |
|---|---|
| Profitability | Solid — Gross margin 77%, operating -58% |
| Balance Sheet | Strong — $218M cash vs $11M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$969K, burning cash |
| Efficiency | Critical — ROE -17%, ROA -11.2% |
Ownership (RXST)
| Insider Ownership | +5.66% |
|---|---|
| Institutional Ownership | +93.25% |
| Shares Outstanding | 41.40M |
| Float | 39.18M |
| Short % of Float | +10.64% |
Source: Nexqual, June 10, 2026 at 03:35 UTC.
Leadership (RXST)
Rxsight, Inc. is led by Ronald M. Kurtz (age 62), President, CEO & Director, per Nexqual as of June 10, 2026 at 03:35 UTC.
| President, CEO & Director | Ronald M. Kurtz (age 62) |
|---|---|
| Chief Operating Officer | Ilya Goldshleger (age 50) |
| Chief Financial Officer | Mark Wilterding (age 47) |
| Vice President of Investor Relations | Oliver Moravcevic |
| Executive Vice President of International | Adam Dashe |
Major Backers & Investors (RXST)
Notable institutional backers of Rxsight, Inc. include Artisan Partners Limited Partnership, Millennium Management, Nomura Holdings Inc., according to Nexqual as of June 10, 2026 at 03:35 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Artisan Partners Limited Partnership | 8.18% |
| Millennium Management | 4.97% |
| Nomura Holdings Inc. | 4.83% |
| No Street GP LP | 4.83% |
| Shaw D.E. & Co., Inc. | 4.73% |
| Two Sigma Investments, LP | 3.14% |
| Bank of America Corporation | 2.92% |
| Healthcare of Ontario Pension Plan Trust Fund | 2.73% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.66% |
| Vanguard Group | 8.04% |
Source: Nexqual, June 10, 2026 at 03:35 UTC.
From Rxsight, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- In the U.S., the world's largest premium IOL market, 2025 premium procedures represented about 21% of all cataract procedures and generated approximately $860 million in revenue, a figure that is projected to grow at a 8.0% compound annual growth rate ("CAGR") by 2030, according to the Market Scope 2025 Premium Cataract Surgery Market Report.
- We are required to manufacture our products in compliance with the FDA's Quality Management System Regulation ("QMSR") (21 CFR Part 820 incorporating ISO 13485:2016), replacing the former Quality System Regulation.
- Our proprietary RxSight ® Light Adjustable Lens system ("RxSight system") is the first and only commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery.
- Our RxSight system is comprised of two key components, along with other intraoperative and postoperative accessories: • RxSight Light Adjustable Lens: The LAL is our proprietary IOL that can be adjusted postoperatively to improve uncorrected visual acuity.
Partnerships
- The facility fees associated with these codes include payment for a conventional IOL of up to $150.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SGHT | Sight Sciences, Inc. | USD 4.85 | ▲ 8.99% |
| TMCI | Treace Medical Concepts, Inc. | USD 3.73 | ▲ 6.27% |
| CTKB | Cytek Biosciences, Inc. | USD 4.13 | ▲ 0.98% |
| CVRX | CVRx, Inc. | USD 5.2 | ▼ 3.35% |
| RPID | Rapid Micro Biosystems, Inc. | USD 1.88 | ▼ 5.53% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:35 UTC. This page is informational and not investment advice.